Quantum BioPharma announces Jack Antel as new clinical advisor to its multiple sclerosis program centered around Lucid-21-302. Dr Antel will be advising Quantum Biopharma on the clinical development of Lucid-MS including design of efficacy trials of Lucid-MS in people with MS. Antel is a Professor of Neurology at McGill University where he has served as Chairman of the Department of Neurology and Neurosurgery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNTM:
- Quantum BioPharma Announces Shareholder Meeting Results
- Quantum BioPharma announces Annual General, Special Meeting results
- Quantum BioPharma’s Licensee Unbuzzd Wellness to Host Investor Webinar on Innovative Hangover Solution
- Quantum BioPharma Receives Health Canada Approval for Qlarity
- Quantum Group announces Health Canada granted Product License for Qlarity